PMID- 7833483
OWN - NLM
STAT- MEDLINE
DCOM- 19950302
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 85
IP  - 3
DP  - 1995 Feb 1
TI  - Leukocyte depletion of random single-donor platelet transfusions does not prevent 
      secondary human leukocyte antigen-alloimmunization and refractoriness: a 
      randomized prospective study.
PG  - 824-8
AB  - We studied the value of leukocyte depletion of platelet transfusions for the 
      prevention of secondary human leukocyte antigen (HLA)-alloimmunization in 
      patients with a high-risk of prior immunization induced by pregnancies. 
      Seventy-five female patients with hematologic malignancies (mostly acute 
      leukemia) and a history of pregnancy were randomized to receive either standard 
      random single-donor platelet transfusions (mean leukocytes, 430 x 10(6) per 
      transfusion) or leukocyte-depleted random single-donor platelet transfusions. 
      Leukocyte depletion to less than 5 x 10(6) leukocytes per platelet transfusion 
      (mean leukocytes, 2 x 10(6) per transfusion) was achieved by filtration. Of the 
      62 evaluable patients, refractoriness to random donor platelets occurred in 41% 
      (14 of 34) of the patients in the standard group and in 29% (8 of 28) of the 
      patients in the filtered group (P = .52); anti-HLA antibodies developed in 43% (9 
      of 21) of individuals in the standard group and 44% (11 of 25) of cases in the 
      filtered group. The time toward refractoriness and development of anti-HLA 
      antibodies was similar for both groups. We conclude that leukocyte depletion of 
      random single-donor platelet products to less than 5 x 10(6) per transfusion does 
      not reduce the incidence of refractoriness to random donor platelet transfusion 
      because of boostering of anti-HLA antibodies.
FAU - Sintnicolaas, K
AU  - Sintnicolaas K
AD  - Department of Statistics, Dr Daniel den Hoed Cancer Center, Rotterdam, The 
      Netherlands.
FAU - van Marwijk Kooij, M
AU  - van Marwijk Kooij M
FAU - van Prooijen, H C
AU  - van Prooijen HC
FAU - van Dijk, B A
AU  - van Dijk BA
FAU - van Putten, W L
AU  - van Putten WL
FAU - Claas, F H
AU  - Claas FH
FAU - Novotny, V M
AU  - Novotny VM
FAU - Brand, A
AU  - Brand A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (HLA Antigens)
RN  - 0 (Isoantibodies)
RN  - 0 (Isoantigens)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - HLA Antigens/immunology
MH  - Humans
MH  - Isoantibodies/*blood
MH  - Isoantigens/immunology
MH  - Leukemia/*therapy
MH  - Leukemia, Myeloid, Acute/therapy
MH  - Leukocytes/*cytology/immunology
MH  - Life Tables
MH  - Lymphoma, Non-Hodgkin/*therapy
MH  - Middle Aged
MH  - Multiple Myeloma/*therapy
MH  - Myelodysplastic Syndromes/*therapy
MH  - *Platelet Transfusion
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy
MH  - Pregnancy
MH  - Prospective Studies
EDAT- 1995/02/01 00:00
MHDA- 1995/02/01 00:01
CRDT- 1995/02/01 00:00
PHST- 1995/02/01 00:00 [pubmed]
PHST- 1995/02/01 00:01 [medline]
PHST- 1995/02/01 00:00 [entrez]
AID - S0006-4971(20)68858-9 [pii]
PST - ppublish
SO  - Blood. 1995 Feb 1;85(3):824-8.